Blogger's Note/Opinion: at the time of the initial publication this blogger attended numerous meetings which critically analyzed the WHI study; fear, poor communication and media hype led to many poor choices without any indepth analysis even at the time; most often the WHI/media were quoted to refer patients to their physicians; those physicians were in the same dilemma as the patients - a mess, in fact; to this day patients/consumers, led by fear, choose to ignore/not believe (?) post-WHI findings and analyses - more on these issues in this article as below
~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Women's Health Initiative study and hormone therapy -- what have we learned 10 years on?
Public release date: 21-May-2012
International Menopause Society
The Women's Health Initiative study and hormone therapy -- what have we learned 10 years on?
In July 2002 the publication of the first Women's Health Initiative
(WHI) report caused a dramatic drop in Menopausal Hormone Therapy (HT )
use throughout the world. Now a major reappraisal by international
experts, published as a series of articles in the peer-reviewed journal
Climacteric
(the official journal of the International Menopause Society), shows
how the evidence has changed over the last 10 years, and supports a
return to a "rational use of HT, initiated near the menopause".
The reappraisal has been carried out by some of the world's leading
experts in the field, including clinicians who worked on the original
WHI study. Summarising the findings of the special issue, authors Robert
Langer, JoAnn Manson, and Matthew Allison conclude that "classical use
of HT" – MHT initiated near the menopause – will benefit most women who
have indications including significant menopausal symptoms or
osteoporosis.
Dr. Robert Langer, Principal Scientist at the Jackson Hole Center for
Preventive Medicine, Jackson Wyoming, was the Principal Investigator of
the WHI Clinical Center at the University of California, San Diego. He
said
"With 10 years hindsight we can put the lessons learned from the WHI
HT trials into perspective. In some ways we've come full circle –
studies in recently menopausal women that suggested protection against
major diseases led to testing whether that would carry over to older
women who have even greater risks of heart attacks and fractures. That
hope proved false. Unfortunately the results were wrongly generalized
back to women like those who inspired the study. Information that has
emerged over the last decade, shows that for most women starting
treatment near the menopause, the benefits outweigh the risks, not just
for relief of hot flashes, night sweats and vaginal dryness, but also
for reducing the risks of heart disease and fractures".
Langer continued:
"
Overgeneralizing the results from the women who were -- on average
-- 12 years past menopause to all postmenopausal women has led to
needless suffering and lost opportunities for many. Sadly, one of the
lessons from the WHI is that starting HT 10 years or more after
menopause may not be a good idea, so the women who were scared away by
the WHI over this past decade may have lost the opportunity to obtain
the potential benefits."
Professor JoAnn Manson (Harvard Medical School and Brigham and
Women's Hospital, Boston, MA), who has been one of the WHI Principal
Investigators since the study started, said:
"An important contribution of the WHI was to clarify that, for older
women at high risk of cardiovascular disease, the risks of HT far
outweighed the benefits. This halted the increasingly common clinical
practice of prescribing HT to women who were far from the onset of
menopause.
Unfortunately, these findings were extrapolated to newly
menopausal and healthy women who actually had a favourable benefit: risk
ratio with HT. The WHI results point the way towards treating each
woman as an individual. There is no doubt that HT is not appropriate for
every woman, but it may be appropriate for many women, and each
individual woman needs to talk this over with her clinician".
The authors note that the initial press reaction, following the lead
of the WHI press release, over-emphasised a relatively small increase
in breast cancer, so distorting the overall view of the report.
WHI researcher Professor Matthew Allison (University of California, San Diego), said:
"It is important to put the results of the WHI trials into context.
That is, being obese, not exercising or excess alcohol consumption
confer higher absolute risks for breast cancer than HT use."
###
Note that a brief summary of the papers in this special issue of
Climacteric appears below.
This special issue, "The Women's Health Initiative – a decade of progress" will appear in the
June 2012 issue of
Climacteric (vol 15, issue 3). This goes on line on 22nd May, at this URL:
http://informahealthcare.com/cmt.
Climacteric is the official journal of the International Menopause Society (IMS).
ABSTRACT:
Have we come full circle-or moved forward? The Women's
Health Initiative 10 years on", by R.D Langer, J.E Manson, and M.A.
Allison,
Climacteric Vol15 no 3 pp206-213
In mid-summer 2002, the announcement that the Women ' s Health
Initiative (WHI) trial of combination hormone therapy (HRT) had stopped
jolted the field of women's health. It set off a cascade that first
stunned, then meaningfully changed the future for millions of women,
their partners, and tens of thousands of clinicians and scientists. With
10 years' hindsight, we can begin to put the lessons learned from the
WHI HRT trials into perspective. These trials were primarily designed to
test whether women initiating HRT considerably past menopause, and
mostly asymptomatic, experienced treatment benefits from HRT expected
from studies of generally symptomatic women who started near menopause.
The definitive answer was ' no ' . Unfortunately, the findings were
generalized to all postmenopausal women regardless of age. Data
accumulated from the WHI and other studies over the past decade have
shown that, in women with symptoms or other indications, initiating HRT
near menopause – the classic pattern of use – will probably provide a
favourable benefit : risk ratio. Spurred by the WHI, many hypotheses
and some insights about potential mechanisms for HRT effects on diverse
organ systems have emerged, along with new perspectives on regimens,
compounds, and routes of administration. This overview provides an
historical perspective on the WHI design and the evolution of its
message; summarizes current perspectives and insights contributed by
eminent colleagues; reviews the state of the art; and looks to the
future. We have come full circle in some ways, with mounting evidence
supporting benefit for HRT started near menopause and with hard lessons
learned about pathophysiology, publicity and interpreting data. Now we
move on.
Summary of papers
This special issue of
Climacteric contains a series of
articles reviewing the position of HRT, 10 years after the WHI. There is
a wealth of information here, which is impossible to communicate in a
single press statement. Here are simplified summaries of each article,
please refer to each individual article for more details.
Quality of Life The WHI study suggested that HRT use led to minimal
improvement in quality of life (QoL). As the WHI study wasn't designed
to look at women going through the menopause, it underestimated the real
extent of effect of HRT on QoL. This has caused suffering to many women
(Pines et al).
HRT for Urogynecological and sexual health Around 50% of
postmenopausal women will suffer urogenital atrophy. Studies indicate
that locally applied hormone therapy is generally more effective than
systemic HRT for urogenital symptoms, including dyspareunia, which can
be a critical determinant of a woman's interest in sex.(Nappi &
Davis)
Timing of HRT initiation, and cost effectiveness The weight of
evidence now supports a ' window-of-opportunity ' for women taking HRT
before the age of 60 and/or within 10 years of the menopause. This
reduces the risk of coronary heart disease and overall mortality. HRT is
more effective for this than other medicines such as statins and
aspirin, and is cost-effective. Starting HRT later than this increases
risks to women (Hodis et al).
Stroke There is a modest increase in stroke risk with HRT use if
stated near the menopause. This risk rises considerably in women who
start at older ages. There is some evidence that use of HRT patches (as
opposed to pills) may not increase stroke risk, but this needs to be
confirmed (Henderson and Lobo).
Venous Thromboembolism There is an increased risk of venous
thromboembolism with oral HRT. This may be increased with age and
obesity, and may vary by the progestogen used. Observational studies
suggest that it may not be associated with transdermal HRTs (patches),
but this needs confirmation (Archer and Ogar).
Breast cancer There is an increase in breast cancer with E+P HRT,
but this is small. It has also been exaggerated by press reports,
causing fear in many women. They conclude that large numbers of women
with substantial menopausal symptoms and low breast cancer risk will
benefit from HRT use (Gompel and Santen).
Colorectal Cancer This is the second most common cancer in women (after
breast cancer). Evidence from the WHI and other trials suggests that
current HRT users have a 40% reduction in colorectal cancers. The
authors say that it is too early to consider HRT use in the prevention
of colon cancer (Barnes and Long)
Dementia Initial WHI results showed an increase in dementia for both
E+P and E alone users. This review including recent publications from
other studies suggests that this may be influenced by the timing of the
HRT initiation, with benefits for those starting nearer the menopause,
but increased risks for women starting at older ages (Maki and
Henderson).
Fractures The WHI "Global Index", which looked at the balance of
risks and benefits, inappropriately downgraded the importance of
fractures. The authors argue for a more rounded view. They say that that
HRT gives more bone benefits than many other drugs (e.g.
bisphosphonates), and so restrictions on HRT use as a first-line therapy
are not appropriate (de Villiers and Stevenson)
Overall effects of the drop in HRT use This is difficult to gauge,
because data varies from country to country. In one large study HRT
discontinuation led to a 55% increase in fractures after 6.5 years.
There was also a small drop in breast cancers after the drop in use in
HRT, most notably in the US, but not seen in all countries, that was
consistent with an effect on existing tumours. HRT discontinuation may
lead to an increase in cardiovascular disease, but given the long lag
time for cardiovascular events this would take substantial time to
become apparent (Burger et al)
The WHI and media The author suggests that the WHI's dramatic
presentation of the initial findings set the subsequent tone for the way
that the media came to view the HRT issue (Simon Brown).
Women who use the oestrogen-only form of hormone replacement therapy
(HRT) appear less likely to develop breast cancer in the longer term,
according to new research published in 
